Asian Pacific Journal of Cancer Prevention

  • 제15권23호
  • /
  • Pages.10171-10174
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Differences in the Prognostic Significance of the SUVmax between Patients with Resected Pulmonary Adenocarcinoma and Squamous Cell Carcinoma

  • Motono, Nozomu (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Ueno, Masakatsu (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Tanaka, Makoto (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Machida, Yuichiro (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Usuda, Katsuo (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Sakuma, Tsutomu (Department of Thoracic Surgery, Kanazawa Medical University) ;
  • Sagawa, Motoyasu (Department of Thoracic Surgery, Kanazawa Medical University)
  • 발행 : 2015.01.06
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: The purpose of this study was to determine the prognostic significance of the maximum standardized uptake value (SUVmax) on F-18-fluorodeoxyglucose (FDG)-positron emission tomography (PET) in patients undergoing surgical treatment for non-small cell lung cancer. Materials and Methods: Seventy-eight consecutive patients (58 with adenocarcinomas, 20 with squamous cell carcinomas) treated with potentially curative surgery were retrospectively reviewed. Results: The SUVmax was significantly higher in the patients with recurrent than with non-recurrent adenocarcinoma (p<0.01). However, among the patients with squamous cell carcinoma, there were no differences with or without recurrence (p=0.69). Multivariate analysis indicated that the SUVmax of adenocarcinoma lesions was a significant predictor of disease-free survival (p=0.04). In addition, an SUVmax of 6.19, the cut-off point based on ROC curve analysis of the patients with pathological IB or more advanced stage adenocarcinomas, was found to be a significant predictor of disease-free survival (p<0.01). Conclusions: SUVmax is a useful predictor of disease-free survival in patients with resected adenocarcinoma, but not squamous cell carcinoma. Patients with adenocarcinoma exhibiting an SUVmax above 6.19 are candidates for more intensive adjuvant therapy.

키워드

참고문헌

  1. Alberts W (2007). Follow up and surveillance of the patient with lung cancer: What do you do after surgery? Respirology, 12, 16-21. https://doi.org/10.1111/j.1440-1843.2006.00956.x
  2. Al-Jahdali H, Khan AN, Loutfi S, Al-Harbi AS (2012). Guidelines for the role of FDG-PET/CT in lung cancer management. J Infect Public Health, 5, 35-40. https://doi.org/10.1016/j.jiph.2011.10.007
  3. Al-Sarraf N, Gately K, Lucey J, et al (2008). Clinical implication and prognostic significance of standardized uptake value of primary non-small cell lung cancer on positron emission tomography:analysis of 176 cases. Eur J Cardiothorac Surg, 34, 892-7. https://doi.org/10.1016/j.ejcts.2008.07.023
  4. de Geus-Oei LF, van der Heijden H, Corstens F, Oyen W (2007). Predictive and prognostic value of FDG-PET in nonsmallcell lung cancer. Cancer, 110, 1654-64. https://doi.org/10.1002/cncr.22979
  5. Ding XP, Zhang J, Li BS, et al (2012). Feasibility of shrinking field radiation therapy through 18F-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers. Asian Pac J Cancer Prev, 13, 319-23. https://doi.org/10.7314/APJCP.2012.13.1.319
  6. Hasbek Z, Yucel B, Salk I, et al (2014). Potential impact of atelectasis and primary tumor glycolysis on F-18 FDG PET/ CT on survival in lung cancer patients. Asian Pac J Cancer Prev, 15, 4085-9. https://doi.org/10.7314/APJCP.2014.15.9.4085
  7. Hicks RJ, Kaiff V, MacManus MP, et al (2001). The utility of 18F-FDG PET for suspected recurrence non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification. J Nucl Med, 42, 1605-13.
  8. Higashi K, Ueda Y, Arisaka Y, et al (2002). 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med, 43, 39-45.
  9. Higuchi M, Hasegawa T, Osugi J, Suzuki H, Gotoh M (2014). Prognostic impact of FDG-PET in surgically treated pathological stage I lung adenocarcinoma. Ann Thorac Cardiovasc Surg, 20, 185-91. https://doi.org/10.5761/atcs.oa.12.02219
  10. Hoekstra C, Stroobants S, Smit E, et al (2005). Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol, 23, 8362-70. https://doi.org/10.1200/JCO.2005.01.1189
  11. Kaya AO, Coskun Y, Unlu M, et al (2008). Whole body 18F-FDG PET/CT imaging in the detection of primary tumors in patients with a metastatic carcinoma of unknown origin. Asian Pac J Cancer Prev, 9, 683-6.
  12. Liu NB, Zhu L, Li MH, et al (2013). Diagnostic value of 18F-FDG PET/CT in comparison to bone scintigraphy, CT and 18F-FDG PET for the detection of bone metastasis. Asian Pac J Cancer Prev, 14, 3647-52. https://doi.org/10.7314/APJCP.2013.14.6.3647
  13. Mac Manus MP, Hicks RJ, Matthews JP, et al (2003). Positron emission tomography is superior to computed tomography scaning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol, 21, 1285-92. https://doi.org/10.1200/JCO.2003.07.054
  14. Martini N, Bains M, Burt M, et al (1995). Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg, 109, 120-9. https://doi.org/10.1016/S0022-5223(95)70427-2
  15. Mutlu H, Buyukcelik A, Erden A, et al (2013). Staging with PET-CT in patients with locally advanced non small cell lung cancer is superior to conventional staging methods in terms of survival. Asian Pac J Cancer Prev, 14, 3743-6. https://doi.org/10.7314/APJCP.2013.14.6.3743
  16. Patz EF Jr, Connolly J, Herndon J (2000). Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR, 174, 769-74. https://doi.org/10.2214/ajr.174.3.1740769
  17. Sasaki R, Komaki R, Macapinlac H, et al (2005). [18F] Fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol, 23, 1136-43. https://doi.org/10.1200/JCO.2005.06.129
  18. Shiono S, Abiko M, Okazaki T, et al (2011) Positron emission tomography for predicting recurrence in stage I lung adenocarcinoma: standardized uptake value corrected by mean liver standardized uptake value. Eur J Cardiothorac Surg, 40, 1165-9.
  19. Sugimura H, Nichols F, Yang P, et al (2007). Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg, 83, 409-18. https://doi.org/10.1016/j.athoracsur.2006.08.046
  20. Vansteekiste JF, Stroobants SG, Dupont PJ, et al (1999). Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer. An analysis of 125 cases. J Clin Oncol, 17, 3201-6.
  21. Walsh G, O'Connor M, Willis K, et al (1995). Is follow-up of lung cancer patients after resection medically indicated and cost-effective? Ann Thorac Surg, 60, 1563-72. https://doi.org/10.1016/0003-4975(95)00893-4
  22. Zhu SH, Zhang Y, Yu YH, et al (2013). FDG PET-CT in nonsmall cell lung cancer: relationship between primary tumor FDG uptake and extensional or metastatic potential. Asian Pac J Cancer Prev, 14, 2925-9. https://doi.org/10.7314/APJCP.2013.14.5.2925